UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet

Annals of oncology, 2011-03, Vol.22 (3), p.723-729

2011

Volltextzugriff (PDF)

Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis

European journal of surgical oncology, 2016-10, Vol.42 (10), p.1552-1560

2016

Volltextzugriff (PDF)

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

Annals of oncology, 2018-10, Vol.29, p.viii251-viii251

2018

Volltextzugriff (PDF)

1558PBiomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

735PReal-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Progression-free survival as a surrogate endpoint in advanced breast cancer

International journal of technology assessment in health care, 2008-10, Vol.24 (4), p.371-383

2008

Volltextzugriff (PDF)

Prostate cancer in a transgender woman 41 years after initiation of feminization

JAMA : the journal of the American Medical Association, 2006-11, Vol.296 (19), p.2316

2006

Volltextzugriff (PDF)

The quality-of-life impact of osteonecrosis of the jaw: Implications for bisphosphonate use in metastatic breast cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.6620-6620

2007

Volltextzugriff (PDF)

Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4081-4081

2010

Volltextzugriff (PDF)

Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14542-e14542

2010

Volltextzugriff (PDF)

Quality of life implications of osteonecrosis of the jaw in cancer patients: a pilot study

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.17557-17557

2008

Volltextzugriff (PDF)

Analysis of hormonal receptor status in tissue from prostate cancer that developed 26 years after bilateral orchiectomy and following 41 years of estrogen therapy

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14610-14610

2006

Volltextzugriff (PDF)

From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa

Journal of urban health, 2005-09, Vol.82 (3), p.498-509

2005

Volltextzugriff (PDF)

Bayesian analysis of the International Adjuvant Lung Trial (IALT): Should it change practice?

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6038-6038

2004

Volltextzugriff (PDF)

Bayesian analysis of the International Adjuvant Lung Trial (IALT): Should it change practice?

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6038-6038

2004

Volltextzugriff (PDF)

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

Cancer, 2019-11, Vol.125 (22), p.4019-4032

2019

Volltextzugriff (PDF)

Real‐World Outcomes of Patients with Metastatic Non‐Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

The oncologist (Dayton, Ohio), 2019-05, Vol.24 (5), p.648-656

2019

Volltextzugriff (PDF)

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

Cancer, 2011-11, Vol.117 (22), p.5094-5102

2011

Volltextzugriff (PDF)

A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

The oncologist (Dayton, Ohio), 2019-02, Vol.24 (2), p.161-e70

2019

Volltextzugriff (PDF)

The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non‐Small Cell Lung Cancer Treated With a PD‐1/PD‐L1 Blocking Antibody Using Real‐World and Trial Data

Clinical pharmacology and therapeutics, 2023-05, Vol.113 (5), p.1139-1149

2023

Volltextzugriff (PDF)

Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy

Surgery, 2017-08, Vol.162 (2), p.275-284

2017

Volltextzugriff (PDF)

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

JAMA oncology, 2018-03, Vol.4 (3), p.e173420

2018

Volltextzugriff (PDF)

Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2019-07, Vol.30, p.iv134-iv134

2019

Volltextzugriff (PDF)

Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Clinical cancer research, 2020-12, Vol.26 (23), p.6158-6167

2020

Volltextzugriff (PDF)

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

The Lancet. Oncology, 2012-01, Vol.13 (1), p.e11-e22

2012

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(82)
Tagungsberichte
(1)

Sprache

Englisch
(83)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet

Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

1558PBiomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)

735PReal-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

Progression-free survival as a surrogate endpoint in advanced breast cancer

Prostate cancer in a transgender woman 41 years after initiation of feminization

The quality-of-life impact of osteonecrosis of the jaw: Implications for bisphosphonate use in metastatic breast cancer

Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients

Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC)

Quality of life implications of osteonecrosis of the jaw in cancer patients: a pilot study

Analysis of hormonal receptor status in tissue from prostate cancer that developed 26 years after bilateral orchiectomy and following 41 years of estrogen therapy

From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa

Bayesian analysis of the International Adjuvant Lung Trial (IALT): Should it change practice?

Bayesian analysis of the International Adjuvant Lung Trial (IALT): Should it change practice?

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

Real‐World Outcomes of Patients with Metastatic Non‐Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non‐Small Cell Lung Cancer Treated With a PD‐1/PD‐L1 Blocking Antibody Using Real‐World and Trial Data

Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

Suchergebnisse filtern